---
title: "Pre-market hot trades in US stocks: Prelude Therapeutics pre-market up 8.44%, driven by positive clinical data and dual benefits from new stock issuance boosting stock price surge"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/283498720.md"
description: "Prelude Therapeutics pre-market up 8.44%; Lobo Tech pre-market up 86.87%; Local Bounti pre-market up 52.13%; SciSparc pre-market up 50.12%"
datetime: "2026-04-21T12:23:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/283498720.md)
  - [en](https://longbridge.com/en/news/283498720.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/283498720.md)
---

# Pre-market hot trades in US stocks: Prelude Therapeutics pre-market up 8.44%, driven by positive clinical data and dual benefits from new stock issuance boosting stock price surge

**Pre-market Hot Trades in US Stocks**

Prelude Therapeutics is up 8.44% in pre-market trading. Based on recent key news:

1.  On April 20, Prelude Therapeutics announced positive clinical data for its experimental breast cancer drug PRT13722, leading to a 13% pre-market stock price increase. The drug demonstrated the ability to effectively degrade the KAT6A protein, driving the stock price up. Source: WSJ
    
2.  On April 20, Prelude Therapeutics announced the issuance of over 18 million shares of common stock at a price of $4.44 per share, with expected total proceeds of approximately $90 million. This move attracted new investors, including RA Capital Management, resulting in a 10.36% pre-market stock price increase. Source: Press Release
    
3.  On April 20, Prelude Therapeutics announced new preclinical data for its lead development candidate PRT13722, causing the stock price to rise. The company plans to submit a new drug application in mid-2026 and begin clinical trials in the second half of the year. Source: WSJ The biotechnology sector has recently performed strongly, with significant capital inflows.
    

**Top Gainers in Pre-market US Stocks**

Lobo Tech is up 86.87% in pre-market trading. Based on recent key news:

1.  On April 21, Lobo Technologies Ltd. released important content via GlobeNewswire, significantly boosting the stock price. The company emphasized its technological innovations and market expansion plans in the press release, attracting investor attention and leading to an 86.87% pre-market stock price increase. Source: GlobeNewswire
    
2.  On April 20, Lobe Sciences Ltd. issued a statement reminding investors to be cautious about forward-looking statements. Nevertheless, market optimism regarding its future growth potential continued to drive the stock price up. Source: ACCESS Newswire
    
3.  On April 20, Lobo Technologies Ltd. released original content via ACCESS Newswire, further solidifying market confidence in its technological capabilities, propelling the stock price up. Source: ACCESS Newswire The technology sector has recently performed strongly, with significant capital inflows.
    

Local Bounti is up 52.13% in pre-market trading, with no significant news recently. Trading is active, and capital flows are evident. Considering sector and industry trends, this stock shows significant volatility, and specific reasons need further observation.

SciSparc is up 50.12% in pre-market trading, with no significant news recently. Trading is active, and capital flows are evident. Considering sector and industry trends, this stock shows significant volatility, and specific reasons need further observation

### Related Stocks

- [PRLD.US](https://longbridge.com/en/quote/PRLD.US.md)

## Related News & Research

- [Prelude Therapeutics Launches Phase 1 Trial and Extends Runway](https://longbridge.com/en/news/286096254.md)
- [Prelude Therapeutics (NASDAQ:PRLD) Rating Lowered to Hold at Wall Street Zen](https://longbridge.com/en/news/272906010.md)
- [Prelude Therapeutics unveils strategic investor presentation on pipelines](https://longbridge.com/en/news/272078759.md)
- [Prelude Therapeutics Inc Announces New Clinical Developments](https://longbridge.com/en/news/272076146.md)
- [Prelude Therapeutics Prices Of $90 Mln Offering Of Shares And Pre-Funded Warrants](https://longbridge.com/en/news/283446003.md)